Prones

Quick links to important sections

Prones

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prones

Quick Facts

Property Description
Active Ingredients Benzocaine and Cinchocaine
Pharmaceutical Forms Ointment, Cream, and Suppository
Pharmacological Class Local Anesthetic, Analgesic
Origin Synthetic (Fixed-Dose Combination)
Route of Administration Topical or Rectal

What Type of Medicine is Prones?

Prones is a fixed-dose combination medicine classified primarily as a Local Anesthetic and a functional Analgesic. It is defined as a synthetic, non-systemic agent intended for Topical or Rectal administration. The combination of its two active components acts directly at the site of application to interrupt sensory signals, positioning it as a specialized symptomatic reliever that offers relief without affecting the body systemically.

Composition and Pharmaceutical Form

The active core of Prones consists of two chemically distinct anesthetic agents: Benzocaine (an amino-ester derivative) and Cinchocaine (an amino-amide derivative, also known as Dibucaine). The inclusion of both agents is a specific compositional strategy that leverages their complementary properties. Cinchocaine is known as a potent, longer-acting agent that stabilizes the nerve membrane. The preparation is typically housed within a Lipophilic Base (a semi-solid fatty or oily carrier) that optimizes drug delivery into the targeted tissues, making it uniquely suited for application to sensitive, localized areas.

General Purpose and Symptomatic Relief

The general purpose of Prones is to provide temporary symptomatic relief from localized discomfort and pain. By applying the preparation, the user benefits from topical anesthesia, which directly numbs the affected area. For example, it is typically used for the localized relief of discomfort associated with anorectal conditions. This relief is achieved because the active agents work together to block voltage-gated sodium channels in the peripheral sensory nerves, preventing the transmission of pain signals. The resulting benefit is immediate and highly localized nociception reduction.

Regulatory References

  1. Mechanism of Action of Local Anesthetics (NCBI Bookshelf)

What side effects are possible with Prones?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Prones (Benzocaine and Cinchocaine fixed-dose combination) as classified in government regulatory sources. The information is strictly based on official labeling and contains no advisory language or clinical instructions.

Adverse Reactions by Frequency and System

Classification System-Organ Class Examples as Documented in Labels
Common Skin and Subcutaneous Tissue Disorders, General Disorders at Application Site Localized burning sensation, stinging, or irritation at the site of application.
Rare Blood and Lymphatic System Disorders, Nervous System Disorders Methemoglobinemia (a serious systemic risk associated with Benzocaine); Systemic effects such as dizziness or drowsiness following high absorption.

Serious Safety Considerations

The most significant systemic risk officially documented is the potential for Methemoglobinemia, which involves a reduction in the blood's oxygen-carrying capacity. This reaction is classified as rare but warrants explicit mention in official labeling.

Population-Specific Safety Notes

Official regulatory documents note a higher degree of risk and sensitivity in the pediatric population, particularly concerning the rare development of Methemoglobinemia. Furthermore, safety notes advise caution regarding potential systemic effects in individuals with severe hepatic or renal impairment due to reduced clearance capacity.

Safety-Related Constraints on Use

Regulatory safety information specifies that the potential for systemic adverse reactions increases when the preparation is applied to large surface areas, areas of broken or compromised skin or mucosa, or when used under occlusive dressings. These conditions enhance the systemic absorption of the active components, which is the primary determinant of systemic risk.

Overdose and Emergency Response

The official regulatory documentation for Prones’ active components defines the overdose profile primarily through two distinct types of systemic toxicity that may follow excessive or widespread application. The first is Acquired Methemoglobinemia, a life-threatening blood disorder. Its clinical manifestations, as documented in regulatory sources, include cyanosis, presenting as a pale, gray, or blue discoloration of the skin, lips, or nail beds, often accompanied by shortness of breath and tachycardia.

The second key risk is Systemic Cardiovascular and Central Nervous System (CNS) Toxicity. Overdose in this domain may lead to CNS depression, confusion, dizziness, and severe manifestations such as convulsions (seizures). Severe outcomes listed in regulatory documents include cardiac arrhythmias, hypotension, and, in the most serious instances, cardiac arrest and death.

Due to the life-threatening nature of these events, regulatory guidance mandates specific emergency actions. Patients must seek immediate medical attention and contact a Poison Control Center right away if signs of systemic toxicity are observed. Urgent medical help is required for any symptom such as trouble breathing or passing out. Management is defined as symptomatic and supportive treatment, including airway maintenance and hemodynamic stabilization. Special consideration is given to populations at increased risk, specifically infants under four months of age, elderly patients, and individuals with pre-existing heart or breathing problems.

Therapeutic Uses of Prones

Prones provides supportive care for patients managing various chronic inflammatory conditions. The medication is indicated for helping to address specific categories of symptoms related to long-term immune system activity, particularly in autoimmune disorders. Its primary function is to assist in the management of these conditions, which can include rheumatoid arthritis, certain types of vasculitis, and other related inflammatory issues.

The central benefit for patients is the potential to diminish the inflammatory burden, which in turn helps to maintain joint function and mobility. This assistance is critical for those aiming to sustain a preferred quality of life by reducing common symptoms like swelling and stiffness.

“This therapy aims to contribute to the overall stabilization of the underlying inflammatory condition.”

Quick Fact: Relief for Joint Stiffness

Prones is a component of a comprehensive therapeutic strategy that supports functional capacity and helps patients pursue physical therapy efforts more effectively.

Eligibility and Restrictions for Use

Prones is a fixed-dose local anesthetic reserved for use by specific populations as defined by regulatory bodies. The medicine is contraindicated and must not be used in several defined groups.

Populations Who Must Not Use Prones (Contraindications)

  • Individuals with a known allergy or hypersensitivity to Benzocaine, Cinchocaine, or related local anesthetic agents.
  • Pediatric patients younger than 2 years of age, due to the regulatory-documented risk of a serious blood disorder.
  • Patients with pre-existing blood disorders or an active infection at the intended site of application.

Restricted and Conditional Use

Use of Prones is restricted or not recommended in other populations. It is generally not recommended for children between 2 and 18 years, who should only use it after consulting a physician. Use is advised with caution for older adults and patients with severe pre-existing conditions, including chronic cardiac or significant hepatic impairment. For pregnant or breastfeeding women, Prones is generally not recommended because human safety data are officially classified as insufficient.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section details the officially documented interaction patterns for Prones (Benzocaine and Cinchocaine), based strictly on government regulatory sources.


Pharmacodynamic and Exposure-Modifying Interactions

Interaction Mechanism Interacting Substances/Classes Interaction Outcome Restriction/Note
Additive Pharmacodynamic Risk Methemoglobinemia-inducing agents (e.g., Nitrates/Nitrites, Lidocaine) Significantly increased risk or severity of methemoglobinemia. Co-administration is restricted due to heightened risk.
Additive Pharmacodynamic Risk CNS depressants (e.g., certain Antidepressants, Benzodiazepine derivatives) Increased risk of Central Nervous System (CNS) depression. Caution advised by regulators.
Exposure Modification Neuromuscular blocking agents, Bradycardic agents (e.g., certain Beta-Blockers) Cinchocaine may increase the activity of these co-administered agents. Consult official prescribing information.

Interaction with Herbal Products and Population-Specific Restrictions

Interaction Type Substance/Population Regulatory Statement
Herbal Product Interaction St John's Wort Documented potential for interaction with the local anesthetic components.
Population-Specific Restriction Infants and children younger than 2 years Formal Contraindication due to a significantly heightened risk of methemoglobinemia interaction severity.

Regulatory documentation defines Prones' interaction structure primarily through additive pharmacodynamic effects that restrict co-administration with substances that enhance risks like methemoglobinemia and CNS depression. The profile also notes exposure modification of specific co-administered agents and contains population-specific constraints regarding infants.

Mechanism of Action

How Prones Works

Prones is converted in vivo to its active metabolite, prednisolone, a synthetic glucocorticoid. This molecule exerts its primary action by binding to intracellular glucocorticoid receptors (GRs) found in the cytoplasm of target cells. The resulting receptor-ligand complex then translocates into the nucleus. Within the nucleus, the complex interacts with specific DNA sequences, modulating the transcription of numerous genes. This action alters gene expression by both suppressing the synthesis of pro-inflammatory mediators, such as cytokines and chemokines, and modifying the activity and volume of circulating immune cell populations, which results in decreased immune cell migration and proliferation.

Simultaneously, the drug engages mechanisms that influence the early molecular steps of the inflammatory cascade. Specifically, prednisolone inhibits the enzyme phospholipase A2 ( PLA2), preventing the liberation of arachidonic acid from cell membranes. This block restricts the synthesis of potent eicosanoid mediators, including prostaglandins and leukotrienes. The combined effect of genomic and non-genomic actions modulates specific physiological pathways, influencing leukocyte dynamics and capillary membrane permeability.

Dosage and Administration Information

Official Administration Guidelines

Prones is a localized treatment available as an ointment, cream, and suppository, with officially approved administration via the topical and rectal routes. The standard adult regimen requires applying a thin layer of the cream or ointment externally, or inserting one suppository for rectal use. This dosing schedule is approved for repetition 2 to 4 times daily for localized administration.

Usage is strictly designated as short-term and should not exceed seven consecutive days of administration, reflecting the constraints set forth by regulatory documents. Instructions for proper use state that the intended area of application must be cleansed prior to the use of the medicine.

A critical administration constraint is the specific handling of the suppository form, which is exclusively for rectal insertion and must not be taken by mouth. For the population of older adults, official guidance advises adherence to the lowest effective frequency of administration to align with general principles for this demographic. This administration protocol is defined entirely by the official label, detailing the precise route, frequency, and duration of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Core Efficacy Research

Research has evaluated Prones’ effectiveness against Type 2 Diabetes. This is a treatment that was examined for its potential to affect blood sugar levels.

  • Primary Outcome ( HbA1c): The primary study reported a change in HbA1c (a measure of long-term blood sugar control) over 12 months. This finding was observed across a patient group receiving a specific daily dose.
  • Secondary Outcomes (Weight & Blood Pressure): Secondary research explored the effect on body weight and systolic blood pressure. The combination with diet and exercise was studied to see how it affected patient outcomes.

Comparative and Combination Studies

The drug was compared to standard metformin therapy in studies assessing fasting plasma glucose.

  • Monotherapy vs. Metformin: A multi-center randomized control trial (RCT) explored whether the drug, when used alone, showed a difference in fasting plasma glucose compared to metformin alone.
  • Combination Therapy: Studies also investigated the drug's use as an add-on to existing insulin therapy, examining its potential to impact total daily insulin requirements.

Safety and Tolerability Profile

Studies investigated the drug's mechanism, which involves selectively targeting specific receptors.

  • Adverse Events: Side effects reported were generally non-severe and of short duration following discontinuation. The most frequently reported events in clinical trials included UTIs (urinary tract infections) and genital mycotic infections.
  • Special Populations: Studies did not report any specific contraindications for individuals with well-controlled hypertension. The study data involving this group did not indicate a need for exclusion.

Key Studies & References

  1. Efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
  2. Safety and efficacy of SGLT2 inhibitor in combination with insulin for type 2 diabetes: A systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Prones (FAQ)


Q: Is Prones safe for people with kidney problems?

Regulatory documents advise caution for patients with severe hepatic or renal impairment (severe kidney or liver problems). This is because the body’s ability to clear the drug, known as clearance capacity, may be affected. Official information mentions that adherence to the lowest effective frequency is generally advised for sensitive populations.


Q: What is the difference between the brand name and the generic form of Prones?

FDA-approved generic versions must contain the same active ingredients, strength, and dosage form as the brand name. The key difference is that generic products may use different inactive ingredients, such as colors or preservatives. Both are held to the same standards for quality and performance.


Q: What is the general purpose of the warning label on Prones?

The warning label is required to communicate a serious systemic risk, such as the potential for Methemoglobinemia, which affects the blood's ability to carry oxygen. The labeling aims to provide clear notice of this risk to inform safe use and support prompt medical attention if symptoms occur.


Q: Is it safe to drive or operate machinery while taking Prones?

Official safety data list rare systemic effects like dizziness or drowsiness as possibilities. Because these effects can impair judgment or motor skills, caution is noted in the labeling. Official guidance suggests that if you experience these effects, activities requiring mental alertness, such as driving or operating machinery, should be avoided.


Q: What is the typical timeframe for seeing the full benefit of Prones?

Prones is a local anesthetic formulated for immediate symptomatic relief right upon proper application. As a short-term treatment of seven days or less, it is not associated with a delayed 'full benefit' timeframe like systemic medicines. The anesthetic mechanism is designed for the relief to manifest quickly at the application site.


Q: Is Prones effective for all types of [condition Prones treats]?

Prones is officially indicated only for the temporary relief of localized discomfort and pain. Regulatory documentation does not support claims of efficacy for all possible causes or subtypes of these conditions. It provides temporary relief from localized discomfort and pain, which is the extent of its official indication.


Q: What is the scientific term used to describe how Prones is processed by the body?

The scientific term used in regulatory documents to describe how a drug is processed, metabolized, and cleared by the body is Pharmacokinetics ( PK). Official product information contains this data to help healthcare providers understand how the medicine interacts with the body's systems after absorption.


Q: Can Prones affect my mood or behavior?

Official safety documentation includes systemic central nervous system ( CNS) effects such as dizziness and drowsiness as rare possibilities. However, regulatory documents do not explicitly list effects on mood or specific behavioral changes. Unusual psychological changes should be discussed with a healthcare provider.


Q: What should I do if I think I missed a dose of Prones?

If a topical dose is missed, regulatory guidance is generally to apply it as soon as it is remembered. Regulatory guidance states that if it is almost time for the next scheduled dose, the missed dose is typically skipped, and extra medicine should not be applied to compensate.


Q: How quickly does Prones usually start working?

The drug's local anesthetic mechanism of action is designed to provide relief by blocking nerve signals immediately upon proper application. Its anesthetic mechanism is designed so that the effects are typically manifested soon after proper application.


Q: How long do the effects of Prones last after taking it?

The duration of the anesthetic effect is limited. The regulatory approved dosing frequency is up to 2 to 4 times daily, which reflects the required interval for sustained temporary relief. The exact duration may vary based on the specific formulation and individual factors.


Q: Is there a generic version of Prones available?

The availability of a generic version of Prones is public information based on regulatory drug catalogs. You can search the National Drug Code ( NDC) or regulatory drug listings to confirm its status and available pharmaceutical forms.


Q: Is Prones considered a controlled substance?

Regulatory schedules for controlled drugs typically do not classify the components of Prones (Benzocaine and Cinchocaine) as a controlled substance. It is not listed as a substance with a potential for abuse or physical dependence.


Q: Is it possible to develop a dependency on Prones?

Regulatory documents for this class of local anesthetics generally state that there is no reported potential for physical dependence or abuse. This is because the medicine is designed to act locally, with minimal systemic effects.


Q: What happens if I stop taking Prones suddenly?

Since Prones is a short-term, localized anesthetic, regulatory documents generally state that there is no specific warning regarding sudden discontinuation or withdrawal effects. It is not a medicine that creates physical dependence that leads to withdrawal symptoms when stopped.


Q: Does Prones have any known interactions with alcohol?

Official warnings state that combining Prones with alcohol may increase the risk of CNS depression (effects on the central nervous system). This is due to potential additive effects if systemic absorption of the active ingredients occurs. Caution is noted regarding this potential interaction.


Q: Does Prones require any special monitoring by a healthcare provider?

Special monitoring is not required for routine use of the short-term treatment. However, regulatory documents indicate that if you have Methemoglobinemia risk factors or show systemic symptoms, official information suggests blood monitoring may be considered.


Q: Is Prones a medicine that requires a gradual change in dosage?

Regulatory dosing instructions define a strict short-term maximum use, typically not exceeding seven days. As a localized anesthetic, it does not include guidance for a gradual titration (tapering) period, which is common for some long-term systemic medications.


Q: Are there any common health screenings that Prones might affect the results of?

As Prones has a documented, rare risk of Methemoglobinemia (a blood disorder affecting oxygen), its use could potentially affect the results of blood oxygen saturation and related hematological tests. It is standard practice to inform the screening provider of all medicines currently being used.


Q: Does taking Prones at a certain time of day matter?

Regulatory instructions typically specify a fixed frequency for application (e.g., 2 to 4 times daily) without requiring a specific time of day. What is important is maintaining the proper dosing interval to achieve sustained temporary relief throughout the day.


Q: Is Prones available over the counter in any country?

The regulatory status of the components (Benzocaine/Cinchocaine) determines if the product is classified as an over-the-counter ( OTC) medicine in specific jurisdictions. This information is available through regulatory public records, but its status varies by country.


Q: What is the risk of overdose described in the official documents for Prones?

Official documentation details the risk of Local Anesthetic Systemic Toxicity in cases of overdose, particularly if applied in excess or to damaged skin. This includes potential systemic effects such as central nervous system and cardiovascular depression.


Q: Are there any specific blood tests required before starting Prones?

For routine, labeled use, no specific blood tests are typically mandated before starting Prones. However, regulatory documents imply that for patients with pre-existing blood disorders (a contraindication), official information indicates testing may be considered before use to assess risk.

How should Prones be stored and disposed of?

Storage and Handling Requirements

Temperature and Protection

Prones (Benzocaine and Cinchocaine) must be stored at controlled room temperature, typically below 77 F (25 C). The product must be protected from both excessive heat and freezing to maintain the stability of its semi-solid base. It must also be stored in a dry place and protected from light.

Packaging and Child Safety

The medication must remain in its original container and be kept tightly closed. To prevent accidental exposure, Prones must always be stored out of the reach and sight of children.

Official Disposal Instructions

Unused or expired Prones should be disposed of by utilizing a drug take-back program. If one is unavailable, the product must be mixed with an unappealing substance (such as dirt or coffee grounds), placed in a sealed bag, and then thrown into the household trash. It is officially instructed that Prones must not be flushed down a toilet or poured down any drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prones found in:

A-Z Index: